Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.
Saba NF, Chaudhary R, Kirtane K, Marra A, Ekpenyong A, McCook-Veal A, Schmitt NC, Gross JH, Patel MR, Remick J, Bates JE, McDonald MW, Rudra SF, Stokes WA, Biernacki M, Song X, Slebos RJC, Liu Y, Steuer CE, Shin DM, Teng Y, Chung CH. Saba NF, et al. Among authors: steuer ce. Clin Cancer Res. 2024 Oct 15;30(20):4601-4608. doi: 10.1158/1078-0432.CCR-24-1202. Clin Cancer Res. 2024. PMID: 39167623 Clinical Trial.
Correction: Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC).
Saba NF, Dinasarapu AR, Magliocca KR, Dwivedi B, Seby S, Qin ZS, Patel M, Griffith CC, Wang X, El-Deiry M, Steuer CE, Kowalski J, Shin DM, Zwick ME, Chen ZG. Saba NF, et al. Among authors: steuer ce. PLoS One. 2024 Aug 8;19(8):e0308819. doi: 10.1371/journal.pone.0308819. eCollection 2024. PLoS One. 2024. PMID: 39116078 Free PMC article.
Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Saba NF, Steuer CE, Ekpenyong A, McCook-Veal A, Magliocca K, Patel M, Schmitt NC, Stokes W, Bates JE, Rudra S, Remick J, McDonald M, Abousaud M, Tan AC, Fadlullah MZH, Chaudhary R, Muzaffar J, Kirtane K, Liu Y, Chen GZ, Shin DM, Teng Y, Chung CH. Saba NF, et al. Among authors: steuer ce. Nat Med. 2024 Aug;30(8):2373. doi: 10.1038/s41591-024-03161-w. Nat Med. 2024. PMID: 38956200 No abstract available.
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations.
Lim AM, Le Tourneau C, Hurt C, Laskar SG, Steuer CE, Chow VLY, Szturz P, Henson C, Day AT, Bates JE, Lazarakis S, McDowell L, Mehanna H, Yom SS; HNCIG. Lim AM, et al. Among authors: steuer ce. Lancet Oncol. 2024 Jul;25(7):e308-e317. doi: 10.1016/S1470-2045(24)00068-8. Lancet Oncol. 2024. PMID: 38936389 Review.
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
Saba NF, Wong SJ, Nasti T, McCook-Veal AA, McDonald MW, Stokes WA, Anderson AM, Ekpenyong A, Rupji M, Abousaud M, Rudra S, Bates JE, Remick JS, Joshi NP, Woody NM, Awan M, Geiger JL, Shreenivas A, Samsa J, Ward MC, Schmitt NC, Patel MR, Higgins KA, Teng Y, Steuer CE, Shin DM, Liu Y, Ahmed R, Koyfman SA. Saba NF, et al. Among authors: steuer ce. JAMA Oncol. 2024 Jul 1;10(7):896-904. doi: 10.1001/jamaoncol.2024.1143. JAMA Oncol. 2024. PMID: 38780927 Clinical Trial.
Assessing survival outcomes of patients with oral tongue squamous cell carcinoma: Focus on age, sex, and stage.
Pamulapati S, Abousaud M, Li Y, Ekpenyong A, Rudra S, Remick JS, Bates JE, Stokes WA, McDonald MW, Schmitt NC, El-Deiry MW, Patel MR, Steuer CE, Switchenko JM, Shin DM, Teng Y, Hammond A, Saba NF. Pamulapati S, et al. Among authors: steuer ce. Head Neck. 2024 Sep;46(9):2167-2177. doi: 10.1002/hed.27786. Epub 2024 May 2. Head Neck. 2024. PMID: 38695445
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
Yu HA, Baik C, Kim DW, Johnson ML, Hayashi H, Nishio M, Yang JC, Su WC, Gold KA, Koczywas M, Smit EF, Steuer CE, Felip E, Murakami H, Kim SW, Su X, Sato S, Fan PD, Fujimura M, Tanaka Y, Patel P, Sternberg DW, Sellami D, Jänne PA. Yu HA, et al. Among authors: steuer ce. Ann Oncol. 2024 May;35(5):437-447. doi: 10.1016/j.annonc.2024.02.003. Epub 2024 Feb 17. Ann Oncol. 2024. PMID: 38369013 Free article. Clinical Trial.
The evolving landscape of salivary gland tumors.
Steuer CE, Hanna GJ, Viswanathan K, Bates JE, Kaka AS, Schmitt NC, Ho AL, Saba NF. Steuer CE, et al. CA Cancer J Clin. 2023 Nov-Dec;73(6):597-619. doi: 10.3322/caac.21807. Epub 2023 Jul 25. CA Cancer J Clin. 2023. PMID: 37490348 Free PMC article. Review.
Patient-reported outcomes in immunotherapy for head and neck cancer.
Kirtane K, Hoogland AI, Li X, Rodriguez Y, Scheel K, Small BJ, Oswald LB, Muzaffar J, Kish JA, Bonomi M, Bhateja P, Saba NF, Steuer CE, Chung CH, Jim HSL. Kirtane K, et al. Among authors: steuer ce. Head Neck. 2023 Jul;45(7):1761-1771. doi: 10.1002/hed.27388. Epub 2023 May 4. Head Neck. 2023. PMID: 37141438
80 results